Jagsonpal Pharmaceuticals Limited
NSE:JAGSNPHARM.NS
539.15 (INR) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,087.02 | 2,367.141 | 2,260.967 | 1,878.756 | 1,585.678 | 1,668.256 | 1,265.329 | 1,438.704 | 1,434.879 | 1,381.509 | 1,438.509 | 1,664.645 | 1,765.139 | 1,609.55 | 1,395.934 | 1,361.976 | 1,500.94 |
| Cost of Revenue
| 1,434.43 | 931.039 | 961.057 | 809.34 | 562.311 | 729.321 | 612.945 | 589.497 | 591.233 | 686.829 | 647.06 | 861.622 | 845.459 | 830.002 | 755.023 | 789.032 | 913.058 |
| Gross Profit
| 652.59 | 1,436.102 | 1,299.91 | 1,069.416 | 1,023.367 | 938.935 | 652.384 | 849.207 | 843.646 | 694.68 | 791.449 | 803.023 | 919.68 | 779.548 | 640.911 | 572.945 | 587.882 |
| Gross Profit Ratio
| 0.313 | 0.607 | 0.575 | 0.569 | 0.645 | 0.563 | 0.516 | 0.59 | 0.588 | 0.503 | 0.55 | 0.482 | 0.521 | 0.484 | 0.459 | 0.421 | 0.392 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 3.458 | 1.541 | 1.209 | 3.743 | 5.644 | 4.688 | 3.285 | 5.548 | 6.933 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 38.05 | 57.64 | 101.728 | 40.694 | 8.968 | 14.965 | 6.93 | 0 | 93.719 | 0 | 0.452 | 0.4 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 163.36 | 186.08 | 153.175 | 129.901 | 178.446 | 131.977 | 112.457 | 0 | 109.955 | 0 | 38.547 | 38.262 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 438.55 | 243.72 | 254.903 | 170.595 | 187.414 | 146.942 | 119.387 | 345.635 | 203.674 | 334.233 | 604.959 | 615.012 | 0 | 0 | 0 | 0 | 0 |
| Other Expenses
| 92.79 | 57.339 | 1.777 | 3.565 | 758.188 | 1.321 | 646.058 | 808.036 | 0.001 | 633.378 | 0.015 | 2.911 | 3.214 | 653.649 | 500.948 | 428.166 | 472.45 |
| Operating Expenses
| 438.55 | 1,106.639 | 1,052.36 | 881.552 | 945.602 | 854.421 | 765.445 | 808.036 | 750.561 | 633.378 | 712.924 | 729.556 | 778.891 | 653.649 | 500.948 | 428.166 | 472.45 |
| Operating Income
| 214.04 | 338.85 | 239.87 | 187.864 | 74.027 | 83.193 | -111.265 | 143.967 | 40.752 | 16.717 | 25.298 | 22.451 | 97.685 | 92.681 | 105.001 | 98.985 | 51.919 |
| Operating Income Ratio
| 0.103 | 0.143 | 0.106 | 0.1 | 0.047 | 0.05 | -0.088 | 0.1 | 0.028 | 0.012 | 0.018 | 0.013 | 0.055 | 0.058 | 0.075 | 0.073 | 0.035 |
| Total Other Income Expenses Net
| 84.65 | 9.23 | 26.55 | 30.859 | 20.121 | 6.835 | -5.002 | 102.796 | -52.332 | -44.585 | -53.212 | -48.104 | -39.89 | -33.218 | -34.962 | -45.793 | -63.514 |
| Income Before Tax
| 298.69 | 348.085 | 273.191 | 218.723 | 94.148 | 90.028 | -116.267 | 143.967 | 40.753 | 16.717 | 25.313 | 25.363 | 100.899 | 92.681 | 105.001 | 98.985 | 51.919 |
| Income Before Tax Ratio
| 0.143 | 0.147 | 0.121 | 0.116 | 0.059 | 0.054 | -0.092 | 0.1 | 0.028 | 0.012 | 0.018 | 0.015 | 0.057 | 0.058 | 0.075 | 0.073 | 0.035 |
| Income Tax Expense
| 74.06 | 80.872 | 77.321 | 48.14 | 15.44 | 17.867 | -0.761 | 25.32 | 8.211 | 5.006 | 4.106 | 7.036 | 26.33 | 20.885 | 12.581 | 37.262 | 21.158 |
| Net Income
| 224.63 | 267.21 | 188.55 | 170.583 | 78.708 | 72.161 | -115.506 | 118.647 | 32.542 | 11.711 | 21.207 | 18.327 | 74.568 | 71.796 | 92.42 | 61.723 | 30.76 |
| Net Income Ratio
| 0.108 | 0.113 | 0.083 | 0.091 | 0.05 | 0.043 | -0.091 | 0.082 | 0.023 | 0.008 | 0.015 | 0.011 | 0.042 | 0.045 | 0.066 | 0.045 | 0.02 |
| EPS
| 8.49 | 10.2 | 7.2 | 6.51 | 3 | 2.75 | -4.41 | 4.53 | 1.24 | 0.45 | 0.81 | 0.7 | 2.85 | 2.74 | 3.76 | 2.35 | 1.17 |
| EPS Diluted
| 8.46 | 10.2 | 7.2 | 6.51 | 3 | 2.75 | -4.41 | 4.53 | 1.24 | 0.45 | 0.81 | 0.7 | 2.85 | 2.74 | 3.76 | 2.35 | 1.17 |
| EBITDA
| 230.67 | 398.856 | 279.802 | 231.353 | 109.437 | 104.629 | -100.642 | 60.955 | 122.76 | 88.371 | 106.779 | 100.543 | 166.147 | 147.908 | 160.813 | 157.276 | 132.304 |
| EBITDA Ratio
| 0.111 | 0.168 | 0.124 | 0.123 | 0.069 | 0.063 | -0.08 | 0.042 | 0.086 | 0.064 | 0.074 | 0.06 | 0.094 | 0.092 | 0.115 | 0.115 | 0.088 |